share_log
Breakings ·  Jun 18 19:34
Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment